

**BEFORE THE  
BOARD OF PHARMACY  
DEPARTMENT OF CONSUMER AFFAIRS  
STATE OF CALIFORNIA**

~~In the Matter of the Accusation Against:~~

~~Case No. 4364~~

**CYNTHIA DAWN GOMEZ**

232 Beverly Court  
King City, CA 93930

Intern Pharmacist Registration Number  
INT 21078

Respondent.


**DECISION AND ORDER**

The attached Stipulated Settlement and Disciplinary Order is hereby adopted by the Board of Pharmacy, Department of Consumer Affairs, as its Decision in this matter.

This decision shall become effective on August 13, 2014.

It is so ORDERED on August 6, 2014.

BOARD OF PHARMACY  
DEPARTMENT OF CONSUMER AFFAIRS  
STATE OF CALIFORNIA



By

\_\_\_\_\_  
STAN C. WEISSER  
Board President

1 KAMALA D. HARRIS  
Attorney General of California  
2 DIANN SOKOLOFF  
Supervising Deputy Attorney General  
3 GREGORY TUSS  
Deputy Attorney General  
4 State Bar Number 200659  
1515 Clay Street, 20th Floor  
5 Post Office Box 70550  
Oakland, California 94612-0550  
6 Telephone: (510) 622-2143  
Facsimile: (510) 622-2270  
7 *Attorneys for Complainant*

8 **BEFORE THE**  
**BOARD OF PHARMACY**  
9 **DEPARTMENT OF CONSUMER AFFAIRS**  
10 **STATE OF CALIFORNIA**

11 In the Matter of the Accusation Against:

12 **CYNTHIA DAWN GOMEZ**  
13 **232 Beverly Court**  
**King City, California 93930**

14 **Intern Pharmacist Registration Number**  
15 **INT 21078,**

16 Respondent.

Case Number 4364  
OAH Number 2013120773

**STIPULATED SETTLEMENT AND**  
**DISCIPLINARY ORDER**

17  
18 IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-  
19 entitled proceedings that the following matters are true:

20 **PARTIES**

21 1. Complainant Virginia Herold is the Executive Officer of the Board of Pharmacy  
22 (Board), Department of Consumer Affairs. She brought this action solely in her official capacity  
23 and is represented in this matter by Kamala D. Harris, Attorney General of the State of California,  
24 and by Gregory Tuss, Deputy Attorney General.

25 2. Respondent Cynthia Dawn Gomez is represented in this proceeding by attorney  
26 Donald Brown, whose address is 3848 Carson Street, Suite 206; Torrance, California 90503.

27 3. On or about September 11, 2007, the Board issued Intern Pharmacist Registration  
28 Number INT 21078 to respondent. The intern pharmacist registration was in full force and effect

1 at all times relevant to the charges brought in Accusation Number 4364. The intern pharmacist  
2 registration expired on May 31, 2013, and has not been renewed.

3 **JURISDICTION**

4 ~~4. Accusation Number 4364 was filed before the Board and is currently pending against~~  
5 respondent. The accusation and all other statutorily required documents were properly served on  
6 respondent on March 28, 2013. Respondent timely filed her notice of defense contesting the  
7 Accusation.

8 5. A copy of Accusation Number 4364 is attached as exhibit 1 and incorporated by  
9 reference.

10 **ADVISEMENT AND WAIVERS**

11 6. Respondent has carefully read, fully discussed with counsel, and understands the  
12 charges and allegations in Accusation Number 4364. Respondent has also carefully read, fully  
13 discussed with counsel, and understands the effects of this Stipulated Settlement and Disciplinary  
14 Order.

15 7. Respondent is fully aware of her legal rights in this matter, including the right to a  
16 hearing on the charges and allegations in the accusation; the right to be represented by counsel at  
17 her own expense; the right to confront and cross-examine the witnesses against her; the right to  
18 present evidence and to testify on her own behalf; the right to the issuance of subpoenas to  
19 compel the attendance of witnesses and the production of documents; the right to reconsideration  
20 and court review of an adverse decision; and all other rights accorded by the California  
21 Administrative Procedure Act and other applicable laws.

22 8. Respondent voluntarily, knowingly, and intelligently waives and gives up each and  
23 every right set forth above.

24 **CULPABILITY**

25 9. Respondent admits the truth of each and every charge and allegation in Accusation  
26 Number 4364.

27 ///

28



1 DISCIPLINARY ORDER

2 IT IS ORDERED that Intern Pharmacist Registration Number INT 21078 issued to  
3 respondent Cynthia Dawn Gomez is reinstated contingent upon respondent reenrolling in a school  
4 of pharmacy recognized by the board to fulfill the education requirements of Business and  
5 Professions Code section 4200, subdivision (a), paragraphs (1) through (4), inclusive. If and  
6 when respondent's intern pharmacist registration is reinstated, it is immediately revoked.  
7 However, the revocation of the intern pharmacist registration is stayed and respondent is placed  
8 on probation for five (5) years subject to the following terms and conditions. Upon respondent's  
9 satisfaction of all probation terms and conditions required for the intern pharmacist registration  
10 and satisfaction of all statutory and regulatory requirements and conditions for issuance of a  
11 pharmacist license, respondent's intern pharmacist license will be cancelled and a pharmacist  
12 license will be issued to respondent. Respondent's pharmacist's license shall be immediately  
13 revoked. The revocation will be stayed, and respondent's pharmacist's license shall be placed on  
14 probation for the time remaining of the five years probation subject to the following terms and  
15 conditions:

16 1. **Obey All Laws**

17 Respondent shall obey all state and federal laws and regulations.

18 Respondent shall report any of the following occurrences to the Board, in writing, within  
19 seventy-two (72) hours of such occurrence:

- 20 • an arrest or issuance of a criminal complaint for violation of any provision of the  
21 Pharmacy Law, state and federal food and drug laws, or state and federal controlled  
22 substances laws  
23 • a plea of guilty or nolo contendere in any state or federal criminal proceeding to any  
24 criminal complaint, information or indictment  
25 • a conviction of any crime  
26 • discipline, citation, or other administrative action filed by any state or federal agency  
27 which involves respondent's intern pharmacist registration or which is related to the  
28

1 practice of pharmacy or the manufacturing, obtaining, handling, distributing, billing,  
2 or charging for any drug, device or controlled substance  
3 Failure to timely report such occurrence shall be considered a violation of probation.

4 **2. Report to the Board**

5 Respondent shall report to the Board quarterly, on a schedule as directed by the Board or its  
6 designee. The report shall be made either in person or in writing, as directed. Among other  
7 requirements, respondent shall state in each report under penalty of perjury whether there has  
8 been compliance with all the terms and conditions of probation. Failure to submit timely reports  
9 in a form as directed shall be considered a violation of probation. Any period(s) of delinquency  
10 in submission of reports as directed may be added to the total period of probation. Moreover, if  
11 the final probation report is not made as directed, probation shall be automatically extended until  
12 such time as the final report is made and accepted by the Board.

13 **3. Interview with the Board**

14 Upon receipt of reasonable prior notice, respondent shall appear in person for interviews  
15 with the Board or its designee, at such intervals and locations as are determined by the Board or  
16 its designee. Failure to appear for any scheduled interview without prior notification to Board  
17 staff, or failure to appear for two (2) or more scheduled interviews with the Board or its designee  
18 during the period of probation, shall be considered a violation of probation.

19 **4. Cooperate with Board Staff**

20 Respondent shall cooperate with the Board's inspection program and with the Board's  
21 monitoring and investigation of respondent's compliance with the terms and conditions of her  
22 probation. Failure to cooperate shall be considered a violation of probation.

23 **5. Continuing Education**

24 Respondent shall provide evidence of efforts to maintain skill and knowledge as a  
25 pharmacist as directed by the Board or its designee.

26 ///

27

28

1           **6. Notice to Employers**

2           · During the period of probation, respondent shall notify all present and prospective  
3 employers of the decision in Case Number 4364 and the terms, conditions and restrictions  
4 imposed on respondent by the decision, as follows:

5           Within thirty (30) days of the effective date of this decision, and within fifteen (15) days of  
6 respondent undertaking any new employment, respondent shall cause her direct supervisor,  
7 pharmacist-in-charge (including each new pharmacist-in-charge employed during respondent's  
8 tenure of employment) and owner to report to the Board in writing acknowledging that the listed  
9 individual(s) has/have read the decision in Case Number 4364, and terms and conditions imposed  
10 thereby. It shall be respondent's responsibility to ensure that her employer(s) and/or supervisor(s)  
11 submit timely acknowledgment(s) to the Board.

12           If respondent works for or is employed by or through a pharmacy employment service,  
13 respondent must notify her direct supervisor, pharmacist-in-charge, and owner at every entity  
14 licensed by the Board of the terms and conditions of the decision in Case Number 4364 in  
15 advance of respondent commencing work at each licensed entity. A record of this notification  
16 must be provided to the Board upon request.

17           Furthermore, within thirty (30) days of the effective date of this decision, and within fifteen  
18 (15) days of respondent undertaking any new employment by or through a pharmacy employment  
19 service, respondent shall cause her direct supervisor with the pharmacy employment service to  
20 report to the Board in writing acknowledging that the supervisor has read the decision in Case  
21 Number 4364 and the terms and conditions imposed thereby. It shall be respondent's  
22 responsibility to ensure that her employer(s) and/or supervisor(s) submit timely  
23 acknowledgment(s) to the Board.

24           Failure to timely notify present or prospective employer(s) or to cause that/those  
25 employer(s) to submit timely acknowledgments to the Board shall be considered a violation of  
26 probation.

27           "Employment" within the meaning of this provision shall include any full-time,  
28 part-time, temporary, relief or pharmacy management service as a pharmacist or any

1 position for which a pharmacist license is a requirement or criterion for employment,  
2 whether respondent is an employee, independent contractor or volunteer.

3 **7. No Supervision of Interns, Serving as Pharmacist-in-Charge (PIC), Serving as**  
4 **Designated Representative-in-Charge, or Serving as a Consultant**

5 During the period of probation, respondent shall not supervise any intern pharmacist, be the  
6 pharmacist-in-charge or designated representative-in-charge of any entity licensed by the Board,  
7 nor serve as a consultant unless otherwise specified in this order. Assumption of any such  
8 unauthorized supervision responsibilities shall be considered a violation of probation.

9 **8. Reimbursement of Board Costs**

10 As a condition precedent to successful completion of probation, respondent shall pay to the  
11 Board its costs of investigation and prosecution in the amount of \$6,002.00. Respondent shall  
12 make said payments pursuant to a payment plan approved by the Board or its designee, so long as  
13 full payment is made within fifty-four (54) months of the effective date of the decision.

14 There shall be no deviation from this schedule absent prior written approval by the Board or  
15 its designee. Failure to pay costs by the deadline(s) as directed shall be considered a violation of  
16 probation.

17 The filing of bankruptcy by respondent shall not relieve respondent of her responsibility to  
18 reimburse the Board its costs of investigation and prosecution.

19 **9. Probation Monitoring Costs**

20 Respondent shall pay any costs associated with probation monitoring as determined by the  
21 Board each and every year of probation. Such costs shall be payable to the Board on a schedule  
22 as directed by the Board or its designee. Failure to pay such costs by the deadline(s) as directed  
23 shall be considered a violation of probation.

24 **10. Status of License**

25 Respondent shall, at all times while on probation, maintain an active, current license with  
26 the Board, including any period during which suspension or probation is tolled. Failure to  
27 maintain an active, current license shall be considered a violation of probation.

28 ///



1 If respondent's license expires or is cancelled by operation of law or otherwise at any time  
2 during the period of probation, including any extensions due to tolling or otherwise, upon renewal  
3 or reapplication respondent's license shall be subject to all terms and conditions of this probation  
4 ~~not previously satisfied.~~

5 **11. License Surrender While on Probation/Suspension**

6 Following the effective date of this decision, should respondent cease practice due to  
7 retirement or health, or be otherwise unable to satisfy the terms and conditions of probation,  
8 respondent may tender her license to the Board for surrender. The Board or its designee shall  
9 have the discretion whether to grant the request for surrender or take any other action it deems  
10 appropriate and reasonable. Upon formal acceptance of the surrender of the license, respondent  
11 will no longer be subject to the terms and conditions of probation. This surrender constitutes a  
12 record of discipline and shall become a part of the respondent's license history with the Board.

13 Upon acceptance of the surrender, respondent shall relinquish her pocket and wall license to  
14 the Board within ten (10) days of notification by the Board that the surrender is accepted.  
15 Respondent may not reapply for any license from the Board for three (3) years from the effective  
16 date of the surrender. Respondent shall meet all requirements applicable to the license sought as  
17 of the date the application for that license is submitted to the Board, including any outstanding  
18 costs.

19 **12. Notification of a Change in Name, Residence Address, Mailing Address or**  
20 **Employment**

21 Respondent shall notify the Board in writing within ten (10) days of any change of  
22 employment. Said notification shall include the reasons for leaving, the address of the new  
23 employer, the name of the supervisor and owner, and the work schedule if known. Respondent  
24 shall further notify the Board in writing within ten (10) days of a change in name, residence  
25 address, mailing address, or phone number.

26 Failure to timely notify the Board of any change in employer(s), name(s), address(es), or  
27 phone number(s) shall be considered a violation of probation.

28 ///

1           **13. Tolling of Probation**

2           Except during periods of suspension, respondent shall, at all times while on probation, be  
3 employed as a pharmacist in California for a minimum of 40 hours per calendar month. Any  
4 month during which this minimum is not met shall toll the period of probation, i.e., the period of  
5 probation shall be extended by one month for each month during which this minimum is not met.  
6 During any such period of tolling of probation, respondent must nonetheless comply with all  
7 terms and conditions of probation.

8           Should respondent, regardless of residency, for any reason (including vacation) cease  
9 practicing as a pharmacist for a minimum of 40 hours per calendar month in California,  
10 respondent must notify the Board in writing within ten (10) days of the cessation of practice, and  
11 must further notify the Board in writing within ten (10) days of the resumption of practice. Any  
12 failure to provide such notification(s) shall be considered a violation of probation.

13           It is a violation of probation for respondent's probation to remain tolled pursuant to the  
14 provisions of this condition for a total period, counting consecutive and non-consecutive months,  
15 exceeding thirty-six (36) months.

16           "Cessation of practice" means any calendar month during which respondent is  
17 not practicing as a pharmacist for at least 40 hours, as defined by Business and  
18 Professions Code section 4000 et seq. "Resumption of practice" means any calendar  
19 month during which respondent is practicing as a pharmacist for at least 40 hours as a  
20 pharmacist as defined by Business and Professions Code section 4000 et seq.

21           **14. Violation of Probation**

22           If a respondent has not complied with any term or condition of probation, the Board shall  
23 have continuing jurisdiction over respondent, and probation shall automatically be extended, until  
24 all terms and conditions have been satisfied or the Board has taken other action as deemed  
25 appropriate to treat the failure to comply as a violation of probation, to terminate probation, and  
26 to impose the penalty that was stayed.

27           If respondent violates probation in any respect, the Board, after giving respondent notice  
28 and an opportunity to be heard, may revoke probation and carry out the disciplinary order that

1 was stayed. Notice and opportunity to be heard are not required for those provisions stating that a  
2 violation thereof may lead to automatic termination of the stay and/or revocation of the license. If  
3 a petition to revoke probation or an accusation is filed against respondent during probation, the  
4 Board shall have continuing jurisdiction and the period of probation shall be automatically  
5 extended until the petition to revoke probation or accusation is heard and decided.

6 **15. Completion of Probation**

7 Upon written notice by the Board or its designee indicating successful completion of  
8 probation, respondent's license will be fully restored.

9 **16. Pharmacists Recovery Program (PRP)**

10 Within thirty (30) days of the effective date of this decision, respondent shall contact the  
11 Pharmacists Recovery Program (PRP) for evaluation, and shall immediately thereafter enroll,  
12 successfully participate in, and complete the treatment contract and any subsequent addendums as  
13 recommended and provided by the PRP and as approved by the Board or its designee. The costs  
14 for PRP participation shall be borne by the respondent.

15 If respondent is currently enrolled in the PRP, said participation is now mandatory and as of  
16 the effective date of this decision is no longer considered a self-referral under Business and  
17 Professions Code section 4362(c)(2). Respondent shall successfully participate in and complete  
18 her current contract and any subsequent addendums with the PRP.

19 Failure to timely contact or enroll in the PRP, or successfully participate in and complete  
20 the treatment contract and/or any addendums, shall be considered a violation of probation.

21 Probation shall be automatically extended until respondent successfully completes the PRP.  
22 Any person terminated from the PRP program shall be automatically suspended by the Board.  
23 Respondent may not resume the practice of pharmacy until notified by the Board in writing.

24 Any confirmed positive test for alcohol or for any drug not lawfully prescribed by a  
25 licensed practitioner as part of a documented medical treatment shall result in the automatic  
26 suspension of practice by respondent and shall be considered a violation of probation.

27 Respondent may not resume the practice of pharmacy until notified by the Board in writing.

28 During suspension, respondent shall not enter any pharmacy area or any portion of the

1 licensed premises of a wholesaler, veterinary food-animal drug retailer or any other distributor of  
2 drugs which is licensed by the Board, or any manufacturer, or where dangerous drugs and devices  
3 or controlled substances are maintained. Respondent shall not practice pharmacy nor do any act

4 involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient  
5 consultation; nor shall respondent manage, administer, or be a consultant to any licensee of the  
6 Board, or have access to or control the ordering, manufacturing or dispensing of dangerous drugs  
7 and controlled substances. Respondent shall not resume practice until notified by the Board.

8 During suspension, respondent shall not engage in any activity that requires the  
9 professional judgment of a pharmacist. Respondent shall not direct or control any aspect of the  
10 practice of pharmacy. Respondent shall not perform the duties of a pharmacy technician or a  
11 designated representative for any entity licensed by the Board.

12 Subject to the above restrictions, respondent may continue to own or hold an interest in any  
13 licensed premises in which she holds an interest at the time this decision becomes effective unless  
14 otherwise specified in this order.

15 Failure to comply with this suspension shall be considered a violation of probation.

16 Respondent shall pay administrative fees as invoiced by the PRP or its designee. Fees not  
17 timely paid to the PRP shall constitute a violation for probation. The Board will collect unpaid  
18 administrative fees as part of the annual probation monitoring costs if not submitted to the PRP.

19 **17. Random Drug Screening**

20 Respondent, at her own expense, shall participate in random testing, including but not  
21 limited to biological fluid testing (urine, blood), breathalyzer, hair follicle testing, or other drug  
22 screening program as directed by the Board or its designee. Respondent may be required to  
23 participate in testing for the entire probation period and the frequency of testing will be  
24 determined by the Board or its designee. At all times, respondent shall fully cooperate with the  
25 Board or its designee, and shall, when directed, submit to such tests and samples for the detection  
26 of alcohol, narcotics, hypnotics, dangerous drugs or other controlled substances as the Board or  
27 its designee may direct. Failure to timely submit to testing as directed shall be considered a  
28 violation of probation. Upon request of the Board or its designee, respondent shall provide

1 documentation from a licensed practitioner that the prescription for a detected drug was  
2 legitimately issued and is a necessary part of the treatment of the respondent. Failure to timely  
3 provide such documentation shall be considered a violation of probation. Any confirmed positive  
4 ~~test for alcohol or for any drug not lawfully prescribed by a licensed practitioner as part of a~~  
5 documented medical treatment shall be considered a violation of probation and shall result in the  
6 automatic suspension of practice of pharmacy by respondent. Respondent may not resume the  
7 practice of pharmacy until notified by the Board in writing.

8 During suspension, respondent shall not enter any pharmacy area or any portion of the  
9 licensed premises of a wholesaler, veterinary food-animal drug retailer or any other distributor of  
10 drugs which is licensed by the Board, or any manufacturer, or where dangerous drugs and devices  
11 or controlled substances are maintained. Respondent shall not practice pharmacy nor do any act  
12 involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient  
13 consultation; nor shall respondent manage, administer, or be a consultant to any licensee of the  
14 Board, or have access to or control the ordering, manufacturing or dispensing of dangerous drugs  
15 and controlled substances. Respondent shall not resume practice until notified by the Board.

16 During suspension, respondent shall not engage in any activity that requires the  
17 professional judgment of a pharmacist. Respondent shall not direct or control any aspect of the  
18 practice of pharmacy. Respondent shall not perform the duties of a pharmacy technician or a  
19 designated representative for any entity licensed by the Board.

20 Subject to the above restrictions, respondent may continue to own or hold an interest in any  
21 licensed premises in which she holds an interest at the time this decision becomes effective unless  
22 otherwise specified in this order.

23 Failure to comply with this suspension shall be considered a violation of probation.

24 **18. Abstain from Drugs and Alcohol Use**

25 Respondent shall completely abstain from the possession or use of alcohol, controlled  
26 substances, dangerous drugs and their associated paraphernalia except when the drugs are  
27 lawfully prescribed by a licensed practitioner as part of a documented medical treatment. Upon  
28 request of the Board or its designee, respondent shall provide documentation from the licensed

1 practitioner that the prescription for the drug was legitimately issued and is a necessary part of the  
2 treatment of the respondent. Failure to timely provide such documentation shall be considered a  
3 violation of probation. Respondent shall ensure that she is not in the same physical location as  
4 individuals who are using illicit substances even if respondent is not personally ingesting the  
5 drugs. Any possession or use of alcohol, controlled substances, or their associated paraphernalia  
6 not supported by the documentation timely provided, and/or any physical proximity to persons  
7 using illicit substances, shall be considered a violation of probation.

8 **19. Prescription Coordination and Monitoring of Prescription Use**

9 Within thirty (30) days of the effective date of this decision, respondent shall submit to the  
10 Board for its prior approval the name and qualifications of a single physician, nurse practitioner,  
11 physician assistant, or psychiatrist of respondent's choice, who shall be aware of the respondent's  
12 history with the use of alcohol, controlled substances, and/or dangerous drugs, and who will  
13 coordinate and monitor any prescriptions for respondent for dangerous drugs, controlled  
14 substances or mood-altering drugs. The approved practitioner shall be provided with a copy of  
15 the Board's accusation and decision. A record of this notification must be provided to the Board  
16 upon request. Respondent shall sign a release authorizing the practitioner to communicate with  
17 the Board about respondent's treatment(s). The coordinating physician, nurse practitioner,  
18 physician assistant, or psychiatrist shall report to the Board on a quarterly basis for the duration of  
19 probation regarding respondent's compliance with this condition. If any substances considered  
20 addictive have been prescribed, the report shall identify a program for the time-limited use of any  
21 such substances. The Board may require that the single coordinating physician, nurse  
22 practitioner, physician assistant or psychiatrist be a specialist in addictive medicine, or consult a  
23 specialist in addictive medicine. Should respondent, for any reason, cease supervision by the  
24 approved practitioner, respondent shall notify the Board immediately and, within thirty (30) days  
25 of ceasing treatment, submit the name of a replacement physician, nurse practitioner, physician  
26 assistant, or psychiatrist of respondent's choice to the Board or its designee for its prior approval.  
27 Failure to timely submit the selected practitioner or replacement practitioner to the Board for  
28 approval, or to ensure the required reporting on the quarterly reports, shall be considered a

1 violation of probation.

2 If at any time an approved practitioner determines that respondent is unable to practice  
3 safely or independently as a pharmacist, the practitioner shall notify the Board immediately by  
4 telephone and follow up by written letter within three (3) working days. Upon notification from  
5 the Board or its designee of this determination, respondent shall be automatically suspended and  
6 shall not resume practice until notified by the Board that practice may be resumed.

7 During suspension, respondent shall not enter any pharmacy area or any portion of the  
8 licensed premises of a wholesaler, veterinary food-animal drug retailer, or any other distributor of  
9 drugs which is licensed by the Board; or any manufacturer; or where dangerous drugs and devices  
10 or controlled substances are maintained. Respondent shall not practice pharmacy nor do any act  
11 involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient  
12 consultation; nor shall respondent manage, administer, or be a consultant to any licensee of the  
13 Board; or have access to or control the ordering, manufacturing or dispensing of dangerous drugs  
14 and controlled substances. Respondent shall not resume practice until notified by the Board.

15 During suspension, respondent shall not engage in any activity that requires the  
16 professional judgment of a pharmacist. Respondent shall not direct or control any aspect of the  
17 practice of pharmacy. Respondent shall not perform the duties of a pharmacy technician or a  
18 designated representative for any entity licensed by the Board.

19 Subject to the above restrictions, respondent may continue to own or hold an interest in any  
20 licensed premises in which she holds an interest at the time this decision becomes effective unless  
21 otherwise specified in this order.

22 Failure to comply with this suspension shall be considered a violation of probation.

23 **20. Supervised Practice**

24 During the period of probation, respondent shall practice only under the supervision of a  
25 licensed pharmacist not on probation with the Board. Upon and after the effective date of this  
26 decision, respondent shall not practice pharmacy and her license shall be automatically suspended  
27 until a supervisor is approved by the Board or its designee. The supervision shall be, as required  
28 by the Board or its designee, either:

1 Continuous – At least 75% of a work week

2 Substantial – At least 50% of a work week

3 Partial – At least 25% of a work week

4 ~~Daily Review – Supervisor's review of probationer's daily activities within 24 hours~~

5 Within thirty (30) days of the effective date of this decision, respondent shall have her  
6 supervisor submit notification to the Board in writing stating that the supervisor has read the  
7 decision in Case Number 4364 and is familiar with the required level of supervision as  
8 determined by the Board or its designee. It shall be the respondent's responsibility to ensure that  
9 her employer(s), pharmacist-in-charge and/or supervisor(s) submit timely acknowledgement(s) to  
10 the Board. Failure to cause the direct supervisor and the pharmacist-in-charge to submit timely  
11 acknowledgements to the Board shall be considered a violation of probation.

12 If respondent changes employment, it shall be the respondent's responsibility to ensure that  
13 her employer(s), pharmacist-in-charge and/or supervisor(s) submit timely acknowledgement(s) to  
14 the Board. Respondent shall have her new supervisor, within fifteen (15) days after employment  
15 commences, submit notification to the Board in writing stating the direct supervisor and  
16 pharmacist-in-charge have read the decision in Case Number 4364 and is familiar with the level  
17 of supervision as determined by the Board. Respondent shall not practice pharmacy and her  
18 license shall be automatically suspended until the Board or its designee approves a new  
19 supervisor. Failure to cause the direct supervisor and the pharmacist-in-charge to submit timely  
20 acknowledgements to the Board shall be considered a violation of probation.

21 Within ten (10) days of leaving employment, respondent shall notify the Board in writing.

22 During suspension, respondent shall not enter any pharmacy area or any portion of the  
23 licensed premises of a wholesaler, veterinary food-animal drug retailer or any other distributor of  
24 drugs which is licensed by the Board; or any manufacturer; or where dangerous drugs and devices  
25 or controlled substances are maintained. Respondent shall not practice pharmacy nor do any act  
26 involving drug selection, selection of stock, manufacturing, compounding, dispensing or patient  
27 consultation; nor shall respondent manage, administer, or be a consultant to any licensee of the  
28 Board; or have access to or control the ordering, manufacturing or dispensing of dangerous drugs



1 and controlled substances. Respondent shall not resume practice until notified by the Board.

2 During suspension, respondent shall not engage in any activity that requires the  
3 professional judgment of a pharmacist. Respondent shall not direct or control any aspect of the  
4 practice of pharmacy. Respondent shall not perform the duties of a pharmacy technician or a  
5 designated representative for any entity licensed by the Board.

6 Subject to the above restrictions, respondent may continue to own or hold an interest in any  
7 licensed premises in which she holds an interest at the time this decision becomes effective unless  
8 otherwise specified in this order.

9 Failure to comply with this suspension shall be considered a violation of probation.

10 **21. No Supervision of Ancillary Personnel**

11 During the period of probation, respondent shall not supervise any ancillary personnel,  
12 including, but not limited to, pharmacy technicians or designated representatives in any entity  
13 licensed by the Board.

14 Failure to comply with this provision shall be considered a violation of probation.

15 **22. No Ownership of Licensed Premises**

16 Respondent shall not own, have any legal or beneficial interest in, or serve as a manager,  
17 administrator, member, officer, director, trustee, associate, or partner of any business, firm,  
18 partnership, or corporation currently or hereinafter licensed by the Board. Respondent shall sell  
19 or transfer any legal or beneficial interest in any entity licensed by the Board within ninety (90)  
20 days following the effective date of this decision and shall immediately thereafter provide written  
21 proof thereof to the Board. Failure to timely divest any legal or beneficial interest(s) or provide  
22 documentation thereof shall be considered a violation of probation.

23 **23. Ethics Course**


24 Within sixty (60) calendar days of the effective date of this decision, respondent shall enroll  
25 in a course in ethics, at respondent's expense, approved in advance by the Board or its designee.  
26 Failure to initiate the course during the first year of probation, and complete it within the second  
27 year of probation, is a violation of probation.

28 Respondent shall submit a certificate of completion to the Board or its designee within five


1 days after completing the course.

ACCEPTANCE

3 I have carefully read the above Stipulated Settlement and Disciplinary Order and have fully  
4 discussed it with my attorney, Donald Brown. I understand the stipulation and the effect it will  
5 have on my intern pharmacist registration. I enter into this Stipulated Settlement and Disciplinary  
6 Order voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order  
7 of the Board of Pharmacy.


8 DATED: 6/26/2014   
9 CYNTHIA DAWN GOMEZ  
Respondent

11 I have read and fully discussed with respondent Cynthia Dawn Gomez the terms and  
12 conditions and other matters contained in the above Stipulated Settlement and Disciplinary Order.  
13 I approve its form and content.

14 DATED: JUL 14 2014   
15 Donald Brown  
Attorney for Respondent

ENDORSEMENT

18 The foregoing Stipulated Settlement and Disciplinary Order is respectfully submitted for  
19 consideration by the Board of Pharmacy.

21 Dated: 7-14-14 Respectfully submitted,  
22 KAMALA D. HARRIS  
Attorney General of California  
23 DIANN SOKOLOFF  
Supervising Deputy Attorney General  
24   
25 GREGORY TUSS  
26 Deputy Attorney General  
27 Attorneys for Complainant

28 SF2012402249

1 days after completing the course.

2 ACCEPTANCE

3 I have carefully read the above Stipulated Settlement and Disciplinary Order and have fully  
4 discussed it with my attorney, Donald Brown. I understand the stipulation and the effect it will  
5 have on my intern pharmacist registration. I enter into this Stipulated Settlement and Disciplinary  
6 Order voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order  
7 of the Board of Pharmacy.

8 DATED: \_\_\_\_\_  
9 CYNTHIA DAWN GOMEZ  
10 Respondent

11 I have read and fully discussed with respondent Cynthia Dawn Gomez the terms and  
12 conditions and other matters contained in the above Stipulated Settlement and Disciplinary Order.  
13 I approve its form and content.

14 DATED: \_\_\_\_\_  
15 Donald Brown  
16 Attorney for Respondent

17 ENDORSEMENT

18 The foregoing Stipulated Settlement and Disciplinary Order is respectfully submitted for  
19 consideration by the Board of Pharmacy.

20 Dated: \_\_\_\_\_  
21 Respectfully submitted,  
22 KAMALA D. HARRIS  
23 Attorney General of California  
24 DIANN SOKOLOFF  
25 Supervising Deputy Attorney General

26 GREGORY TUSS  
27 Deputy Attorney General  
28 *Attorneys for Complainant*

SF2012402249

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28

**Exhibit 1**

**Accusation Number 4364**

1 KAMALA D. HARRIS  
Attorney General of California  
2 DIANN SOKOLOFF  
Supervising Deputy Attorney General  
3 GREGORY TUSS  
Deputy Attorney General  
4 State Bar Number 200659  
1515 Clay Street, 20th Floor  
5 Post Office Box 70550  
Oakland, California 94612-0550  
6 Telephone: (510) 622-2143  
Facsimile: (510) 622-2270  
7 *Attorneys for Complainant*

8 **BEFORE THE**  
9 **BOARD OF PHARMACY**  
10 **DEPARTMENT OF CONSUMER AFFAIRS**  
11 **STATE OF CALIFORNIA**

11 In the Matter of the Accusation Against:

Case Number 4364

12 **CYNTHIA DAWN GOMEZ**  
13 7531 Poppy Lane  
Fontana, California 92336

**ACCUSATION**

14 Intern Pharmacist License Number  
15 INT 21078

16 Respondent.

17  
18 Complainant Virginia Herold alleges:

19 **PARTIES**

- 20 1. Complainant brings this Accusation solely in her official capacity as the Executive  
21 Officer of the Board of Pharmacy (Board), Department of Consumer Affairs.  
22 2. On or about September 11, 2007, the Board issued Intern Pharmacist License Number  
23 INT 21078 to respondent Cynthia Dawn Gomez. This intern pharmacist license was in full force  
24 and effect at all times relevant to the charges brought in this Accusation and will expire on May  
25 31, 2013, unless renewed.

26 **JURISDICTION**

- 27 3. This Accusation is brought before the Board under the authority of the following  
28 laws. All section references are to the Business and Professions Code unless otherwise indicated.

1 4. Section 118, subdivision (b), provides:

2 "The suspension, expiration, or forfeiture by operation of law of a license issued by a board  
3 ~~in the department, or its suspension, forfeiture, or cancellation by order of the board or by order~~  
4 of a court of law, or its surrender without the written consent of the board, shall not, during any  
5 period in which it may be renewed, restored, reissued, or reinstated, deprive the board of its  
6 authority to institute of continue a disciplinary proceeding against the licensee upon any ground  
7 provided by law or to enter an order suspending or revoking the license or otherwise taking  
8 disciplinary action against the licensee on any such ground."

9 5. Section 4011 provides:

10 "The board shall administer and enforce this chapter and the Uniform Controlled  
11 Substances Act (Division 10 (commencing with Section 11000) of the Health and Safety Code)."

12 6. Section 4300 provides, in pertinent part:

13 "(a) Every license issued may be suspended or revoked."

14 7. Section 4304 provides:

15 "The board may deny, revoke, or suspend any license issued pursuant to Section 4161 for  
16 any violation of this chapter or for any violation of Part 5 (commencing with Section 109875) of  
17 Division 104 of the Health and Safety Code."

18 **STATUTORY PROVISIONS**

19 8. Section 4060 provides, in pertinent part:

20 "No person shall possess any controlled substance, except that furnished to a person upon  
21 the prescription of a physician, dentist, podiatrist, optometrist, veterinarian, or naturopathic doctor  
22 pursuant to Section 3640.7, or furnished pursuant to a drug order issued by a certified nurse-  
23 midwife pursuant to Section 2746.51, a nurse practitioner pursuant to Section 2836.1, a physician  
24 assistant pursuant to Section 3502.1, a naturopathic doctor pursuant to Section 3640.5, or a  
25 pharmacist pursuant to either Section 4052.1 or 4052.2."

26 ///

27

28

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

9. Section 4301 provides, in pertinent part:

“The board shall take action against any holder of a license who is guilty of unprofessional conduct or whose license has been procured by fraud or misrepresentation or issued by mistake.

Unprofessional conduct shall include, but is not limited to, any of the following:

...

“(f) The commission of any act involving moral turpitude, dishonesty, fraud, deceit, or corruption, whether the act is committed in the course of relations as a licensee or otherwise, and whether the act is a felony or misdemeanor or not.

...

“(h) The administering to oneself, of any controlled substance, or the use of any dangerous drug or of alcoholic beverages to the extent or in a manner as to be dangerous or injurious to oneself, to a person holding a license under this chapter, or to any other person or to the public, or to the extent that the use impairs the ability of the person to conduct with safety to the public the practice authorized by the license.

...

“(j) The violation of any of the statutes of this state, of any other state, or of the United States regulating controlled substances and dangerous drugs.

...

“(o) Violating or attempting to violate, directly or indirectly, or assisting in or abetting the violation of or conspiring to violate any provision or term of this chapter or of the applicable federal and state laws and regulations governing pharmacy, including regulations established by the board or by any other state or federal regulatory agency.”

10. Section 4327 provides:

“Any person who, while on duty, sells, dispenses or compounds any drug while under the influence of any dangerous drug or alcoholic beverages shall be guilty of a misdemeanor.”

11. Health and Safety Code section 11055 provides, in pertinent part:

“(a) The controlled substances listed in this section are included in Schedule II.

...



1 "d) Stimulants. Unless specifically excepted or unless listed in another schedule, any  
2 material, compound, mixture, or preparation which contains any quantity of the following  
3 ~~substances having a stimulant effect on the central nervous system:~~

4 "(1) Amphetamine, its salts, optical isomers, and salts of its optical isomers.

5 ...

6 "(3) Dimethylamphetamine (N,N-dimethylamphetamine), its salts, isomers, and salts of its  
7 isomers.

8 ...

9 "(6) Methylphenidate."

10 12. Health and Safety Code section 11170 provides:

11 "No person shall prescribe, administer, or furnish a controlled substance for himself."

12 **COST RECOVERY**

13 13. Section 125.3 provides, in pertinent part:

14 "(a) Except as otherwise provided by law, in any order issued in resolution of a disciplinary  
15 proceeding before any board within the department or before the Osteopathic Medical Board,  
16 upon request of the entity bringing the proceedings, the administrative law judge may direct a  
17 licentiate found to have committed a violation or violations of the licensing act to pay a sum not  
18 to exceed the reasonable costs of the investigation and enforcement of the case."

19 **DRUGS**

20 14. "Amphetamine" is a Schedule II controlled substance pursuant to Health and Safety  
21 Code section 11055, subdivision (d)(1).

22 15. "Dextroamphetamine," also known by the brand names "Dexedrine" and  
23 "Dextrostat," is used to treat attention-deficit hyperactivity disorder and narcolepsy. It is a  
24 Schedule II controlled substance pursuant to Health and Safety Code section 11055, subdivision  
25 (d)(1), and a dangerous drug within the meaning of Business and Professions Code section 4022.

26 16. "Dextroamphetamine-Amphetamine ER" and "amphetamine salts," also known by  
27 the brand name "Adderall," is used to treat attention-deficit hyperactivity disorder and  
28 narcolepsy. It is a Schedule II controlled substance pursuant to Health and Safety Code section

1 11055, subdivision (d)(1), and a dangerous drug within the meaning of Business and Professions  
2 Code section 4022.

3 17. "Dimethylphenidate," also known by the brand name "Focalin," is used to treat  
4 attention-deficit hyperactivity disorder. It is a Schedule II controlled substance pursuant to  
5 Health and Safety Code section 11055, subdivision (d)(3), and a dangerous drug within the  
6 meaning of Business and Professions Code section 4022.

7 18. "Lisdexamfetamine," also known by the brand name "Vyvase," is used to treat  
8 attention-deficit hyperactivity disorder. It is a Schedule II controlled substance pursuant to  
9 Health and Safety Code section 11055, subdivision (d)(1), and a dangerous drug within the  
10 meaning of Business and Professions Code section 4022.

11 19. "Methylphenidate," also known by the brand names "Concerta," "Methylin,"  
12 "Metadate," and "Ritalin," is used to treat attention-deficit hyperactivity disorder. It is a Schedule  
13 II controlled substance pursuant to Health and Safety Code section 11055, subdivision (d)(6), and  
14 a dangerous drug within the meaning of Business and Professions Code section 4022.

15 **FACTUAL BACKGROUND**

16 20. On or about July 14, 2011, respondent began as a pharmacist intern at Bertelli's  
17 Health Mart Pharmacy #3 in King City, California. On or about July 20, 2011, a pharmacy  
18 technician found a manufacturer's bottle of Dextroamphetamine in the storeroom between two  
19 binders of pharmacy reports. The bottle contained different pills of Dextroamphetamine,  
20 Methylphenidate, Dimethylphenidate, and amphetamine salts. The pharmacy technician reported  
21 the bottle to the pharmacist in charge (PIC). While the pharmacy technician and the PIC were  
22 investigating the bottle in the storeroom, respondent left the work she was assigned at the  
23 pharmacy counter and joined them in the storeroom. She appeared interested in their  
24 investigation. The PIC sent respondent back to her work.

25 21. The PIC telephoned another staff pharmacist to ask whether she knew of any  
26 problems with medications. That staff pharmacist said that respondent sent her a text message on  
27 or about July 14, 2011, stating that she accidentally took home a manufacturer's stock bottle of  
28 drugs. The staff pharmacist at the time told respondent to return the drugs the next day. That

1 next day, another pharmacy technician reported to the staff pharmacist that she saw a  
2 manufacturer's bottle of Lisdexamphetamine in respondent's purse. The staff pharmacist assumed  
3 that this bottle was the drugs that respondent said that she had accidentally taken home.

4 22. After the Dextroamphetamine bottle was found in the storeroom and the PIC was  
5 informed of respondent taking drugs home, he asked her to submit to drug testing. Respondent  
6 agreed. The initial lab results of respondent's urine sample taken on July 20, 2011, were  
7 inconclusive; the lab said it appeared that respondent diluted the sample with toilet water because  
8 it was the incorrect color and temperature. The lab sent the sample for additional testing.

9 23. The PIC suspended respondent pending the test results. Respondent told the PIC that  
10 she did not tamper with her urine sample. When the PIC asked respondent about the  
11 Lisdexamphetamine that was seen in her purse (which he assumed was the drugs that respondent  
12 said that she had accidentally taken home and was returning), respondent denied taking  
13 Lisdexamphetamine home. Respondent said she took home a NSAID (non-steroidal anti-  
14 inflammatory drug). Respondent agreed to another drug test, but refused to take the test with a  
15 witness present.

16 24. On or about July 29, 2013, the lab's additional testing determined that respondent's  
17 urine sample tested positive for amphetamines. A Controlled Substance Utilization Review and  
18 Evaluation System (CURES) report showed no record of respondent having received an  
19 amphetamine-related medication during the time of the test.

20 25. The PIC inventoried the pharmacy's Schedule II controlled substances and found the  
21 following losses that occurred sometime between July 14 and July 20, 2011:

- 22 • 50 20 mg capsules Lisdexamphetamine
- 23 • 8 20 mg tablets Dimethylphenidate
- 24 • 11 25 mg capsules Dextroamphetamine-Amphetamine ER
- 25 • 7 10 mg tablets amphetamine salts
- 26 • 104 10 mg tablets Dextroamphetamine
- 27 • 6 36 mg tablets Methylphenidate
- 28 • 8 20 mg tablets Methylphenidate

- 1 • 13. 40 mg capsules - Methylphenidate

2 26. On or about July 22, 2011, respondent was interviewed by the police. She stated that  
3 ~~she could not remember what drugs she accidentally took home on July 14, but believed they~~  
4 were an anti-inflammatory medication. The officer asked about the Lisdexamfetamine in  
5 respondent's purse. At first she denied having accidentally taken it home. Respondent then said  
6 that it was possible that she accidentally took home Lisdexamfetamine and not a NSAID. She  
7 also stated that her urine sample became contaminated when she dropped it in the toilet. She did  
8 not take a second drug test at the time because she could not urinate any more. She said she had  
9 not used amphetamines and that her only addiction was to alcohol.

10 27. On or about November 11, 2011, respondent was admitted to a residential treatment  
11 program for alcohol dependency.

12 28. On or about June 19, 2012, the Board's investigator interviewed respondent.  
13 Respondent again stated that her urine sample became contaminated when she dropped it in the  
14 toilet. She refused to take a second drug test because she did not want to work for people who did  
15 not trust her. She denied taking any drugs from the pharmacy. She said she was on medication  
16 when she was working at the pharmacy but refused to state what those medications were.

17 29. When the investigator confronted respondent with her positive drug test, respondent  
18 admitted to taking amphetamines a few days before the drug test. She said they were given to her  
19 by a friend because respondent was feeling tired. Even though the inventory showed  
20 Lisdexamfetamine missing from the pharmacy, respondent maintained that she returned the  
21 Lisdexamfetamine that was found in her purse. She again denied taking any drugs from the  
22 pharmacy.

23 **CAUSES FOR DISCIPLINE**

24  
25 **FIRST CAUSE FOR DISCIPLINE**  
26 **Unprofessional Conduct – Act of Moral Turpitude,**  
27 **Dishonesty, Fraud, Deceit, or Corruption**  
28 **Bus. & Prof. Code, § 4301, subd. (f)**

29. The allegations of paragraphs 20-29 are realleged and incorporated by reference as if  
fully set forth.

1           30. Respondent has subjected her intern pharmacist license to disciplinary action under  
2 section 4301, subdivision (f), for the unprofessional conduct of committing an act of moral  
3 ~~turpitude, dishonesty, fraud, deceit, or corruption. As set forth in paragraphs 20-29 above,~~  
4 respondent possessed Lisdexamfetamine without a prescription or any authorization from the  
5 pharmacy.

6                                   **SECOND CAUSE FOR DISCIPLINE**  
7                           **Unprofessional Conduct – Possession of Controlled Substance**  
8                           **Bus. & Prof. Code, §§ 4060, 4301, subs. (j) & (o)**

9           31. The allegations of paragraphs 20-29 are realleged and incorporated by reference as if  
10 fully set forth.

11           32. Respondent has subjected her intern pharmacist license to disciplinary action under  
12 sections 4060 and 4301, subdivisions (j) and (o), for the unprofessional conduct of possession of a  
13 controlled substance. As set forth in paragraphs 20-29 above, respondent possessed  
14 Lisdexamfetamine without a prescription or any authorization from the pharmacy.

15                                   **THIRD CAUSE FOR DISCIPLINE**  
16                           **Unprofessional Conduct – Possession of Controlled Substance**  
17                           **Bus. & Prof. Code, §§ 4060, 4301, subs. (j) & (o)**

18           33. The allegations of paragraphs 20-29 are realleged and incorporated by reference as if  
19 fully set forth.

20           34. Respondent has subjected her intern pharmacist license to disciplinary action under  
21 sections 4060 and 4301, subdivisions (j) and (o), for the unprofessional conduct of possession of a  
22 controlled substance. As set forth in paragraphs 20-29 above, respondent tested positive for  
23 amphetamines and admitted taking amphetamines that were given to her by a friend.

24                                   **FOURTH CAUSE FOR DISCIPLINE**  
25                           **Unprofessional Conduct – Self-Administration of a Controlled Substance**  
26                           **Bus. & Prof. Code, § 4301, subd. (h)**

27           35. The allegations of paragraphs 20-29 are realleged and incorporated by reference as if  
28 fully set forth.

36. Respondent has subjected her intern pharmacist license to disciplinary action under  
section 4301, subdivisions (h), for the unprofessional conduct of self-administration of a

///

1 controlled substance. As set forth in paragraphs 20-29 above, respondent tested positive for  
2 amphetamines and admitted taking amphetamines that were given to her by a friend.

3 ~~FIFTH CAUSE FOR DISCIPLINE~~

4 **Unprofessional Conduct – Self-Administration of a Controlled Substance**  
5 **Bus. & Prof. Code, § 4301, subd. (j); Health & Saf. Code, § 11170**

6 37. The allegations of paragraphs 20-29 are realleged and incorporated by reference as if  
7 fully set forth.

8 38. Respondent has subjected her intern pharmacist license to disciplinary action under  
9 Business and Professions Code section 4301, subdivision (j), and Health and Safety Code section  
10 11170, for the unprofessional conduct of self-administration of a controlled substance. As set  
11 forth in paragraphs 20-29 above, respondent tested positive for amphetamines and admitted  
12 taking amphetamines that were given to her by a friend.

13 **SIXTH CAUSE FOR DISCIPLINE**

14 **Unprofessional Conduct – Under the Influence While on Duty**  
15 **Bus. & Prof. Code, §§ 4301, subds. (j) & (o), 4327**

16 39. The allegations of paragraphs 20-29 are realleged and incorporated by reference as if  
17 fully set forth.

18 40. Respondent has subjected her intern pharmacist license to disciplinary action under  
19 Business and Professions Code sections 4301, subdivisions (h) and (j), and 4327, for the  
20 unprofessional conduct of being under the influence while on duty as a pharmacist intern. As set  
21 forth in paragraphs 20-29 above, respondent tested positive for amphetamines when respondent  
22 was at work and admitted taking amphetamines a few days before the test.

23 **SEVENTH CAUSE FOR DISCIPLINE**

24 **Unprofessional Conduct – Use of Alcoholic Beverages**  
25 **Bus. & Prof. Code, § 4301, subd. (h)**

26 41. The allegations of paragraphs 20-29 are realleged and incorporated by reference as if  
27 fully set forth.

28 42. Respondent has subjected her intern pharmacist license to disciplinary action under  
section 4301, subdivisions (h), for the unprofessional conduct of use of alcoholic beverages to the  
extent or in a manner as to be dangerous or injurious to herself, to any other person, to the public,  
or to the extent that the use impaired her ability to conduct with safety to the public the practice of

1 a pharmacist intern. As set forth in paragraphs 20-29 above, respondent admitted that she had an  
2 addiction to alcohol and went to a residential treatment program for alcohol dependency.  
3 Respondent's alcohol use was to an extent or in a manner as to be dangerous or injurious to  
4 herself, to any other person, to the public, or to the extent that the use impaired her to conduct  
5 with safety to the public the practice of a pharmacist intern.

6 **PRAYER**


7 WHEREFORE, complainant requests that a hearing be held on the matters alleged in this  
8 Accusation, and that following the hearing, the Board issue a decision:

9 1. Revoking or suspending Intern Pharmacist License Number INT 21078 issued to  
10 Cynthia Dawn Gomez;

11 2. Ordering Cynthia Dawn Gomez to pay the Board the reasonable costs of the  
12 investigation and enforcement of this case pursuant to Business and Professions Code section  
13 125.3; and

14 3. Taking such other and further action as deemed necessary and proper.

15 DATED: 3/21/13



16 VIRGINIA HEROLD  
17 Executive Officer  
18 Board of Pharmacy  
19 Department of Consumer Affairs  
20 State of California  
21 Complainant

22 SF2012402249  
23 90285553.doc  
24  
25  
26  
27  
28